Study of Insulin Pump in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia

University Hospital, Grenoble20 enrolled

Overview

The main objective is to evaluate the efficacy of sensor augmented pump (SAP) therapy with MiniMed 640G with SmartGuard activation in preventing hypoglycemia events in comparison sensor augmented pump (SAP) therapy with Minimed 640G without SmartGuard activation in type 1 diabetic adults with an increased risk of hypoglycemia. The study should show: * A reduction in the number of severe hypoglycemia, fewer hypoglycemic events and a reduction in the time spent in hypoglycemia six months in any group compared to Baseline. * A complete prevention of severe and not severe hypoglycemia in the pump group Minimed 640G + Enlite sensor with SmartGuard activation

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Diabetes, Type 1

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 1 or insulin-dependent diabetic patients * Patients treated with subcutaneous insulin pump with at least 2 episodes of severe hypoglycemia within 12 months before the study enrollment * Affiliation to the french social security system or equivalent * People who signed the consent form Exclusion Criteria: * Patient who have difficulty to understand the French language * Patient can not be raised to the use of an insulin pump, or a glucose sensor * Patient visually impaired * Patient hard of hearing * Pregnant woman or woman having a project of pregnancy within 6 months * Persons referred to in Articles L1121-5 to L1121-8 CSP: pregnant woman, woman in labor, breastfeeding women, persons deprived of their liberty by judicial or administrative decision, person under a legal protection measure.

Locations (2)

Grenoble University Hospital

Grenoble, France

Montpellier University Hospital

Montpellier, France

Outcomes

Primary Outcomes

Assessment of the Minimed 640G insulin pump with Smartguard activation in preventing the number of severe and non-severe hypoglycaemia in patients with diabetes type 1 at risk of severe hypoglycemia

Number of events of hypoglycemia (severe and non-severe)

Time frame: 6 months

Secondary Outcomes

Assessment of Improving of overall glycemic control with SmartGuard activation in type 1 diabetic patients at risk of severe hypoglycemia

Comprehensive metabolic evaluation data and evaluation data of severe hypoglycaemic risk

Time frame: 6 months

Assessment of the quality of life of patients with smartguard activation

Quality of Life Questionnaire

Time frame: 6 months

Assessment of the number of adverse events

Assessment of the safety of the sensor augmented pump therapy with the Mimimed 640G insulin pump coupled with a 640G Minimed Enlite sensor with Smart Guard as compare to sensor augmented pump therapy with the Mimimed 640G insulin pump coupled with a 640G Minimed Enlite sensor without Smart Guard activation (Decompensated ketoacidosis, Hospitalization related to severe hypoglycemia or frequent hypoglycemia or moderate decompensation, Materiovigilance data, Collection and monitoring of serious adverse events and non-serious)

Time frame: 6 months

Study of average cost per patient for each therapeutic strategy supported from the point of view of society

An average cost per patient will be calculated for each strategy. The horizon time is 6 months from randomization of the patient.

Time frame: 6 months